Watson Pharmaceuticals
This article was originally published in The Tan Sheet
Executive Summary
New York City appeals court will consider on Jan. 13 SmithKline Beecham's request that the preliminary injunction barring distribution of Watson's private label nicotine polacrilex gum not be lifted. A Manhattan district court modified the injunction Dec. 22 allowing Watson to ship the gum with a revised user's guide and audiocassette; the revised versions were approved by FDA Dec. 27. SB (maker of Nicorette) appealed the court's decision and a stay has been granted until the appeals court ruling. SmithKline originally filed suit Aug. 26, alleging copyright infringement due to Watson's identical user's guide and audiocassette (1"The Tan Sheet" Sept. 6, 1999, p. 3)
You may also be interested in...
SmithKline Seeks Injunction Against Watson Nicotine Gum Labeling
SmithKline Beecham Consumer Healthcare alleges copyright infringement of the company's Nicorette smoking cessation gum in a lawsuit filed against Watson Pharmaceuticals and its subsidiaries, Watson Laboratories and Circa Pharmaceuticals, Aug. 26.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands